webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Mal-PEG4-Val-Cit-PAB-PNP

  CAS No.: 2112738-09-5   Cat No.: BADC-01065   Purity: >98.0% 4.5  

Mal-PEG4-Val-Cit-PAB-PNP is a maleimide-functionalized cleavable ADC linker with PEG spacer and valine-citrulline peptide for enzyme-triggered drug release in antibody-drug conjugates.

Mal-PEG4-Val-Cit-PAB-PNP

Structure of 2112738-09-5

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Linker
Molecular Formula
C40H53N7O15
Molecular Weight
871.89
Shipping
Room temperature, or blue ice upon request.
Shipping
Store at 4 °C

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
4-((17S,20S)-1-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-17-isopropyl-15,18-dioxo-20-(3-ureidopropyl)-3,6,9,12-tetraoxa-16,19-diazahenicosan-21-amido)benzyl (4-nitrophenyl) carbonate
IUPAC Name
Canonical SMILES
CC(C)C(C(=O)NC(CCCNC(=O)N)C(=O)NC1=CC=C(C=C1)COC(=O)OC2=CC=C(C=C2)[N+](=O)[O-])NC(=O)CCOCCOCCOCCOCCN3C(=O)C=CC3=O
InChI
InChI=1S/C40H53N7O15/c1-27(2)36(45-33(48)15-18-57-20-22-59-24-25-60-23-21-58-19-17-46-34(49)13-14-35(46)50)38(52)44-32(4-3-16-42-39(41)53)37(51)43-29-7-5-28(6-8-29)26-61-40(54)62-31-11-9-30(10-12-31)47(55)56/h5-14,27,32,36H,3-4,15-26H2,1-2H3,(H,43,51)(H,44,52)(H,45,48)(H3,41,42,53)/t32-,36-/m0/s1
InChIKey
ZEPYLTPLLQQBNX-IKYOIFQTSA-N
Solubility
10 mm in DMSO
Shelf Life
0-4°C for short term (days to weeks), or -20°C for long term (months).
Shipping
Room temperature, or blue ice upon request.
Storage
Store at 4 °C

Mal-PEG4-Val-Cit-PAB-PNP is a specialized bioconjugation reagent designed for use in targeted drug delivery systems, including antibody-drug conjugates (ADCs) and other precision therapies. The compound incorporates a maleimide (Mal) group for conjugation to thiol-containing biomolecules such as peptides, antibodies, or proteins, a polyethylene glycol (PEG4) spacer for enhanced solubility and stability, and a Val-Cit-PAB-PNP (valine-citrulline-p-aminobenzyloxycarbonyl-p-nitrophenyl) linker. The PNP group facilitates the release of the drug payload upon enzymatic cleavage, making this compound ideal for controlled and selective drug delivery to disease sites.

One of the primary applications of Mal-PEG4-Val-Cit-PAB-PNP is in the development of antibody-drug conjugates (ADCs) for cancer therapy. The maleimide group enables conjugation with monoclonal antibodies, which target specific tumor antigens, while the PEG4 spacer enhances the pharmacokinetics of the conjugate by improving solubility and reducing immunogenicity. The Val-Cit-PAB-PNP linker is cleaved by tumor-specific proteases, allowing for the release of cytotoxic drugs directly at the tumor site. The PNP group facilitates controlled drug release, ensuring that the therapeutic agent is delivered selectively to cancer cells, minimizing systemic toxicity, and enhancing the overall efficacy of the treatment.

Mal-PEG4-Val-Cit-PAB-PNP is also utilized in the development of other targeted drug delivery systems, such as those for RNA-based therapies, small molecules, or gene therapies. The PEG4 spacer not only improves the solubility and stability of the conjugate but also prolongs its circulation time in the bloodstream, ensuring more efficient delivery to the target site. The cleavable linker ensures that the therapeutic agent is released at the disease site in response to enzymatic activity, offering precise control over drug release. This makes Mal-PEG4-Val-Cit-PAB-PNP ideal for designing personalized therapies, where drugs can be selectively delivered to tissues or organs that express specific biomarkers, such as tumors or infected tissues.

In addition to its role in drug delivery, Mal-PEG4-Val-Cit-PAB-PNP is also valuable in biomolecule labeling and protein conjugation applications. The maleimide group enables covalent attachment to thiol-containing molecules, while the PEG4 spacer ensures stability and solubility in aqueous solutions. The PNP group can be used for bioorthogonal reactions, allowing for precise labeling or tracking of biomolecules. This compound is particularly useful in proteomics, cell biology, and molecular imaging applications, where accurate biomolecule detection and analysis are required for understanding cellular processes, protein interactions, and disease mechanisms.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Linker Development Enzyme Cleavable Linker Cathepsin B Cleavable Linker/Peptide Linker Phosphatase Cleavable Linker β-Glucuronide Linker β-Galactosidase Cleavable Linker Sulfatase Cleavable Linker Chemically Cleavable Linker Non-Cleavable Linker Services Acid Cleavable Linker/Hydrazone Linker

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Linkers - A Crucial Factor in Antibody–Drug Conjugates In-Depth Review of ADC Linkers: Types, Mechanisms, and Research Progress New Structural Insights Solve Instability Issues of Maleimide Linkers in ADCs PEG Linkers in Antibody-Drug Conjugates Peptide Linkers in Antibody-Drug Conjugates Disulfide Linkers in Antibody-Drug Conjugates Biotinylation Reagents in Antibody-Drug Conjugates Maleimide Linkers in Antibody-Drug Conjugates Current ADC Linker Chemistry SPDB Linkers in Antibody-Drug Conjugates

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: BCN-exo-PEG3-maleimide | BCN-exo-PEG8-NHS | Ansamitocin P 3' | Mal-PEG2-Val-Cit-PABA | Mal-PEG8-Val-Cit-PAB-MMAE | BCN-PEG3-VC-PFP ester | PBD dimer | Calicheamicin | Mal-amido-PEG2-Val-Cit-PAB-PNP | MC-Val-Cit-PAB | Mal-PEG4-Val-Cit-PAB-PNP
Send Inquiry
Verification code
Inquiry Basket